AFLAC INC

Company Overview

Aflac Inc. is a global supplemental life and health insurer with two reporting segments: Aflac Japan (the largest earnings contributor and a market leader in cancer insurance) and Aflac U.S. (a mix of individual portable and group supplemental products). The company’s results are materially driven by investment income, foreign-exchange translation (yen/USD), reserve remeasurements in Japan, and seasonal sales patterns (notably Q4 U.S. group sales). Recent financials show modest revenue growth and strong adjusted profitability in 2024 (adjusted earnings ~$4.1B) but pronounced quarter-to-quarter volatility driven by investment mark-to-market and FX (Q2 2025 net investment losses of $421M).

Executive Compensation Practices

Compensation is likely calibrated to insurance-specific performance levers: adjusted earnings, pretax adjusted margins by segment, return on equity/adjusted-book value, and underwriting metrics (benefit and expense ratios) rather than raw GAAP earnings given large investment and FX noise. Long-term incentives in the Financial Services / Insurance - Life industry typically use a mix of restricted stock, performance shares and deferred awards tied to multi-year ROE, adjusted-book growth, capital adequacy (SMR/RBC/ESR) and multi-year underwriting outcomes; Aflac’s large sensitivity of LFPB to discount rates (±100 bps = +$9.6B/−$7.6B) and emphasis on capital targets make solvency and ALM goals likely vesting conditions. Management also highlights capital returns ( ~$2.8B repurchases in 2024 and $1.7B YTD in 2025; a 16% dividend increase announced for 2025), so board pay decisions may reflect a tradeoff between shareholder distributions and retention of capital for regulatory buffers. Given investment and FX volatility and hedging programs, compensation plans will commonly rely on “adjusted” metrics and include clawbacks, deferral and risk-based governance to align pay with long-term solvency.

Insider Trading Considerations

Insider transaction patterns at Aflac will often reflect the company’s capital actions and market-sensitive earnings drivers: executives may sell shares following sizable buyback programs or after dividend hikes, and they may opportunistically buy when share price weakness is driven by temporary investment/FX losses. Expect heightened trading restrictions and blackout periods around quarterly results, material events (e.g., the June 2025 cybersecurity incident), and during major capital or hedging initiatives (yen note issuances, internal reinsurance changes) — and a prevalence of pre-arranged 10b5-1 plans for disciplined trading given recurring volatility. For traders and researchers, monitor Form 4 filings clustered after repurchase announcements or when adjusted metrics diverge from GAAP, and watch for insider activity around FX-driven earnings swings and regulatory capital disclosures (SMR/RBC/ESR), which can materially affect executive incentive outcomes and timing of insider sales.